Lakefront Biotherapeutics NV, formerly known as Galapagos NV, is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel medicines for serious diseases with high unmet medical needs. Founded in 1999 and headquartered in Mechelen, Belgium, the company historically built a strong research platform and achieved commercial stage with the rheumatoid arthritis drug Jyseleca. However, following a major strategic reset, the company divested its Jyseleca business and transitioned away from its earlier cell therapy ambitions.
Today, Lakefront Biotherapeutics operates with a modality-agnostic asset selection approach, primarily focusing on immunology, inflammation, and oncology. The company's pipeline is anchored by T-cell engager programs, including gamgertamig (OM336), a clinical-stage BCMAxCD3 T-cell engager acquired through its strategic acquisition of Ouro Medicines in collaboration with Gilead Sciences. This lead asset is being developed for severe immune-mediated and autoimmune diseases.
Lakefront's business model centers on transformational business development, leveraging its substantial capital reserves to identify, acquire, and advance promising clinical-stage opportunities. The company generates revenue primarily through milestone payments, royalties, and strategic collaborations, most notably its long-standing partnership with Gilead Sciences. With operations spanning Europe and the United States (including a corporate hub in Chicago), Lakefront aims to build a differentiated pipeline of breakthrough therapies while maintaining operational flexibility and disciplined capital allocation.
